Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28:9:925211.
doi: 10.3389/fcvm.2022.925211. eCollection 2022.

Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail?

Jun-Jun Yeh  1   2 , Tuey-Wen Hung  3 , Cheng-Li Lin  2   4 , Tsung-Tse Chen  3 , Pei-Xuan Liw  3 , Ya-Lun Yu  3 , Chia-Hung Kao  5   6   7   8
Affiliations

Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail?

Jun-Jun Yeh et al. Front Cardiovasc Med. .

Abstract

Background: This study investigated the effect of colchicine use on the risks of heart disease (HD), pericarditis, endocarditis, myocarditis, cardiomyopathy, cardiac arrhythmia, and cardiac failure in patients having interstitial lung disease (ILD) with virus infection (ILD cohort).

Methods: We retrospectively enrolled ILD cohort between 2000 and 2013 from the Longitudinal Health Insurance Database and divided them into colchicine users (n = 12,253) and colchicine non-users (n = 12,253) through propensity score matching. The event of interest was the diagnosis of HD. The incidence of HD was analyzed using multivariate Cox proportional hazards models between colchicine users and the comparison cohort after adjustment for age, sex, medication, comorbidities, and index date based on the time-dependent analysis.

Results: Colchicine users had a significantly lower risk of HD (aHR = 0.87, 95% confidence interval (CI]) = 0.82-0.92) than did the colchicine non-user. For colchicine non-users as the reference, the aHR (95% CI) of the patients who received colchicine of 2-7, 8-30, 31-150, and > 150 days were 0.89 (0.81-0.98), 0.84 (0.76-0.94), 090 (0.80-0.99), and 0.83 (0.74-0.93), respectively; regardless of duration use, the lower risk of HD persisted in colchicine users. The cumulative incidence of HD in colchicine users was significantly lower than that in the colchicine non-users (log-rank p < 0.001).

Conclusion: The addition of short-term or long-term colchicine to standard medical therapy may have benefits to prevent the HD among the ILD patients concurrent with a virus infection or comorbidities even in elderly patients.

Keywords: cardiomyopathy; colchicine; endocarditis; myocarditis; pericarditis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow chart.
FIGURE 2
FIGURE 2
The selection of patients and definition of the study cohort and speculation of this study.
FIGURE 3
FIGURE 3
Cumulative incidence of heart disease curves for colchicine users and colchicine non-users by propensity score matched.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yafasova A, Fosbøl Emil L, Schou M, Baslund B, Faurschou M, Docherty Kieran F, et al. Long-term cardiovascular outcomes in systemic lupus erythematosus. J Am Coll Cardiol. (2021) 77:1717–27. - PubMed
    1. An N, Gao Y, Si Z, Zhang H, Wang L, Tian C, et al. Regulatory mechanisms of the NLRP3 inflammasome, a novel immune-inflammatory marker in cardiovascular diseases. Front Immunol. (2019) 10:1592. 10.3389/fimmu.2019.01592 - DOI - PMC - PubMed
    1. Effendi WI, Nagano T. The crucial role of NLRP3 inflammasome in viral infection-associated fibrosing interstitial lung diseases. Int J Mol Sci. (2021) 22:10447. 10.3390/ijms221910447 - DOI - PMC - PubMed
    1. Huang WJ, Tang XX. Virus infection induced pulmonary fibrosis. J Transl Med. (2021) 19:496. - PMC - PubMed
    1. Mostafaei S, Sayad B, Azar MEF, Doroudian M, Hadifar S, Behrouzi A, et al. The role of viral and bacterial infections in the pathogenesis of IPF: a systematic review and meta-analysis. Respir Res. (2021) 22:53. 10.1186/s12931-021-01650-x - DOI - PMC - PubMed

LinkOut - more resources